The U.S. Food and Drug Administration on Saturday warned patients across the country of faulty batches of the supplement L-Citrulline, an amino acid used to treat genetic disorders mostly in children, Reuters reported.

The supplements manufacturer, New York-based Medisca Inc., issued a voluntary recall of eight lots of the supplement after testing indicated that it does not contain any L-citrulline/

The products have already been distributed to hospitals and retail pharmacies, according to FDA officials. The federal agency said it has received "several adverse event reports associated with Medisca's L-citrulline product."

"Health care professionals should discontinue dispensing from these lots, contact patients, and return all unused product to Medisca Inc.," FDA officials said in an advisory.

The FDA said testing performed by Medisca indicated that L-citrulline, lot numbers 95482/A, 95482/B, 95482/C, 95482/D and 96453/A, 96453/B, 96453/C, 96453/D do not contain L-citrulline. Pharmacists should see updated FDA Statement below for more product details.

FDA officials said the affected lots represent a potential health hazard and should not be used for any purpose.